VEXAS syndrome

Last updated

VEXAS syndrome is an adult-onset autoinflammatory disease primarily affecting males, caused by a somatic mutation of the UBA1 gene in hematopoietic progenitor cells. [1] [2] [3] [4] [5] The name VEXAS is an acronym deriving from the core features of disease: [6]

Contents

V: Vacuoles are often identified in the bone marrow stem cells of patients presenting with VEXAS.
E: The E1 ubiquitin conjugating enzyme encoded by the UBA1 gene is mutated in patients.
X: The mutated UBA1 gene is recessive and located on the X-chromosome and thus the disease is almost exclusively found in individuals with a single X chromosome and thus said to be X-linked.
A: Patients with VEXAS present with a wide array of Autoinflammatory conditions
S: The mutations which cause VEXAS are Somatic: they are acquired throughout life, not inherited, and are not passed on to offspring.

Signs and symptoms

The disease arises in late adulthood (typically after the age of 50) and causes both autoinflammatory and hematologic symptoms. [7] Fever and skin conditions—particularly rashes resembling those seen in Sweet syndrome—are common signs. Other autoinflammatory conditions that can occur in individuals with VEXAS syndrome include periorbital angioedema, uveitis and scleritis, relapsing polychondritis, and polyarteritis nodosa. Inflammation may also affect the lungs. [7] [8]

Hematologic issues include macrocytic anemia, a low platelet count, and a predisposition towards developing hematologic malignancies, especially myelodysplastic syndrome. On bone marrow examination, people with the disease exhibit abnormal vacuoles in precursor cells of the myeloid and erythroid lineages. [7]

Treatment

VEXAS syndrome becomes more severe over time and carries a high mortality rate. Symptoms can be managed with high-dose corticosteroid therapy, but this can cause serious adverse effects, and symptoms typically recur after the dosage is lowered. For this reason, a variety of alternative treatments were under investigation as of 2021. [7] [8] The molecular mechanism of VEXAS is currently unknown.

History and discovery

The syndrome was identified by a multidisciplinary team of clinicians and scientists led by David B. Beck, Peter Grayson, and Daniel L. Kastner. [9] [10] The supplemental section of the journal article of the discovery elucidates that the initial discovery of the mutation was made by Daron Ross in the first 2 patients identified. [9] It was first reported in The New England Journal of Medicine in October 2020 where Beck et al wrote: "Using a genotype-driven approach, we identified a disorder that connects seemingly unrelated adult-onset inflammatory syndromes". [9]

An editorial in the same issue describes the work as a "fascinating discovery" which "is of immediate importance to rheumatologists and has far-reaching consequences of general clinical interest. It builds on previous findings suggesting that postzygotic somatic mutation may be a more frequent cause of human disease than previously recognized". [11] In 2022, the American Society of Hematology deemed the discovery of VEXAS the "year's best advancement in hematology-related diagnoses", and that researching VEXAS would potentially improve the classification of hematologic (blood-based) and adult-onset recurrent autoimmune diseases such as relapsing polychondritis. [12]

Investigations

Since VEXAS was first described in 2020, there has been global interest in understanding the disease. In 2022 the National Cancer Institute announced a three-year clinical trial to evaluate stem cell transplant as a possible treatment for patients with VEXAS. [13] Scientists, including David B. Beck, one of the original discoverers, at the New York University Grossman School of Medicine and NYU Langone Health were also actively researching the condition. [14] [15] [16] [17]

Related Research Articles

<span class="mw-page-title-main">Crohn's disease</span> Type of inflammatory bowel disease

Crohn's disease is a type of inflammatory bowel disease (IBD) that may affect any segment of the gastrointestinal tract. Symptoms often include abdominal pain, diarrhea, fever, abdominal distension, and weight loss. Complications outside of the gastrointestinal tract may include anemia, skin rashes, arthritis, inflammation of the eye, and fatigue. The skin rashes may be due to infections as well as pyoderma gangrenosum or erythema nodosum. Bowel obstruction may occur as a complication of chronic inflammation, and those with the disease are at greater risk of colon cancer and small bowel cancer.

<span class="mw-page-title-main">Relapsing polychondritis</span> Medical condition

Relapsing polychondritis is a systemic disease characterized by repeated episodes of inflammation and in some cases deterioration of cartilage. The disease can be life-threatening if the respiratory tract, heart valves, or blood vessels are affected. The exact mechanism is poorly understood.

<span class="mw-page-title-main">Pyoderma gangrenosum</span> Medical condition

Pyoderma gangrenosum is a rare, inflammatory skin disease where painful pustules or nodules become ulcers that progressively grow. Pyoderma gangrenosum is not infectious.

Immune reconstitution inflammatory syndrome (IRIS) is a condition seen in some cases of HIV/AIDS or immunosuppression, in which the immune system begins to recover, but then responds to a previously acquired opportunistic infection with an overwhelming inflammatory response that paradoxically makes the symptoms of infection worse.

<span class="mw-page-title-main">Febrile neutrophilic dermatosis</span> Medical condition

Sweet syndrome (SS), or acute febrile neutrophilic dermatosis, is a skin disease characterized by the sudden onset of fever, an elevated white blood cell count, and tender, red, well-demarcated papules and plaques that show dense infiltrates by neutrophil granulocytes on histologic examination.

Periodic fever syndromes are a set of disorders characterized by recurrent episodes of systemic and organ-specific inflammation. Unlike autoimmune disorders such as systemic lupus erythematosus, in which the disease is caused by abnormalities of the adaptive immune system, people with autoinflammatory diseases do not produce autoantibodies or antigen-specific T or B cells. Instead, the autoinflammatory diseases are characterized by errors in the innate immune system.

Chronic recurrent multifocal osteomyelitis (CRMO) is a rare condition (1:1,000,000), in which the bones have lesions, inflammation, and pain. It is called multifocal because it can appear in different parts of the body, primarily bones, and osteomyelitis because it is very similar to that disease, although CRMO appears to be without any infection.

Schnitzler syndrome or Schnitzler's syndrome is a rare disease characterised by onset around middle age of chronic hives (urticaria) and periodic fever, bone pain and joint pain, weight loss, malaise, fatigue, swollen lymph glands and enlarged spleen and liver.

<span class="mw-page-title-main">Cryopyrin-associated periodic syndrome</span> Medical condition

Cryopyrin-associated periodic syndrome (CAPS) is a group of rare, heterogeneous autoinflammatory disease characterized by interleukin 1β-mediated systemic inflammation and clinical symptoms involving skin, joints, central nervous system, and eyes. It encompasses a spectrum of three clinically overlapping autoinflammatory syndromes including familial cold autoinflammatory syndrome, the Muckle–Wells syndrome (MWS), and neonatal-onset multisystem inflammatory disease that were originally thought to be distinct entities, but in fact share a single genetic mutation and pathogenic pathway, and keratoendotheliitis fugax hereditaria in which the autoinflammatory symptoms affect only the anterior segment of the eye.

Periodontitis as a manifestation of systemic diseases is one of the seven categories of periodontitis as defined by the American Academy of Periodontology 1999 classification system and is one of the three classifications of periodontal diseases and conditions within the 2017 classification. At least 16 systemic diseases have been linked to periodontitis. These systemic diseases are associated with periodontal disease because they generally contribute to either a decreased host resistance to infections or dysfunction in the connective tissue of the gums, increasing patient susceptibility to inflammation-induced destruction.
These secondary periodontal inflammations should not be confused by other conditions in which an epidemiological association with periodontitis was revealed, but no causative connection was proved yet. Such conditions are coronary heart diseases, cerebrovascular diseases and erectile dysfunction.

Mouth and genital ulcers with inflamed cartilage syndrome or MAGIC syndrome refers to a condition in which an individual exhibits symptoms of both relapsing polychondritis (RP) and Behcet's disease (BD). Inflammatory ulcers in the mouth, genitalia, and skin are the hallmark of Behcet's disease (BD), a multisystem illness that is chronic and relapsing. Autoimmune recurrent chondritis of the larynx, tracheobronchial tree, nose, ears, and mouth is known as relapsing polychondritis (RP).

Neal Stuart Young is an American physician and researcher, chief of the Hematology Branch of the National Institutes of Health (NIH), and Director of the Center for Human Immunology at the NIH in Bethesda, Maryland. He is primarily known for his work in the pathophysiology and treatment of aplastic anemia, and is also known for his contributions to the pathophysiology of parvovirus B19 infection.

STAT3 gain-of function (GOF) is a rare genetic disorder of the immune system, leading to early-onset autoimmunity and a variety of multi-organ disorders. The condition is progressive and manifests through a broad spectrum of clinical symptoms, including lymphadenopathy, autoimmune cytopenias, growth delays, enteropathy, lung disease, endocrine disorders, arthritis, autoimmune hepatitis, neurological diseases, vasculopathy, eczema, infections, and multiorgan autoimmunity. Patients experience recurring infections.

Clonal hypereosinophilia, also termed primary hypereosinophilia or clonal eosinophilia, is a grouping of hematological disorders all of which are characterized by the development and growth of a pre-malignant or malignant population of eosinophils, a type of white blood cell that occupies the bone marrow, blood, and other tissues. This population consists of a clone of eosinophils, i.e. a group of genetically identical eosinophils derived from a sufficiently mutated ancestor cell.

GATA2 deficiency is a grouping of several disorders caused by common defect, namely, familial or sporadic inactivating mutations in one of the two parental GATA2 genes. Being the gene haploinsufficient, mutations that cause a reduction in the cellular levels of the gene's product, GATA2, are autosomal dominant. The GATA2 protein is a transcription factor critical for the embryonic development, maintenance, and functionality of blood-forming, lymphatic-forming, and other tissue-forming stem cells. In consequence of these mutations, cellular levels of GATA2 are deficient and individuals develop over time hematological, immunological, lymphatic, or other presentations that may begin as apparently benign abnormalities but commonly progress to severe organ failure, opportunistic infections, virus infection-induced cancers, the myelodysplastic syndrome, and/or leukemia. GATA2 deficiency is a life-threatening and precancerous condition.

<span class="mw-page-title-main">Adenosine deaminase 2 deficiency</span> Medical condition

Deficiency of Adenosine deaminase 2 (DADA2) is a monogenic disease associated with systemic inflammation and vasculopathy that affects a wide variety of organs in different patients. As a result, it is hard to characterize a patient with this disorder. Manifestations of the disease include but are not limited to recurrent fever, livedoid rash, various cytopenias, stroke, immunodeficiency, and bone marrow failure. Symptoms often onset during early childhood, but some cases have been discovered as late as 65 years old.

<span class="mw-page-title-main">Epstein syndrome</span> Medical condition

Epstein syndrome is a rare genetic disease characterized by a mutation in the MYH9 gene in nonmuscle myosin. This disease affects the patient's renal system and can result in kidney failure. Epstein syndrome was first discovered in 1972 when two families had similar symptoms to Alport syndrome. Epstein syndrome and other Alport-like disorders were seen to be caused by mutations in the MYH9 gene, however, Epstein syndrome differs as it was more specifically linked to a mutation on the R702 codon on the MYH9 gene. Diseases with mutations on the MYH9 gene also include May–Hegglin anomaly, Sebastian syndrome and Fechtner syndrome.

<span class="mw-page-title-main">Daniel L. Kastner</span> American physician and researcher

Daniel L. Kastner is an American physician and researcher specialising in the genetics of autoinflammatory disorders. He is scientific director of the National Human Genome Research Institute, where he is a National Institutes of Health Distinguished Investigator. He was awarded the 2021 Crafoord Prize for Polyarthritis for his pioneering work on autoinflammatory diseases.

Autoinflammatory diseases (AIDs) are a group of rare disorders caused by dysfunction of the innate immune system. These responses are characterized by periodic or chronic systemic inflammation, usually without the involvement of adaptive immunity.

<span class="mw-page-title-main">David B. Beck</span> American clinical geneticist

David B. Beck is an American physician-scientist, clinical geneticist, and researcher who co-discovered VEXAS Syndrome. He holds dual appointments as an assistant professor in the Department of Medicine and the Department of Biochemistry and Molecular Pharmacology, and is a member of the Center for Human Genetics and Genomics and the Division of Rheumatology at New York University Grossman School of Medicine and NYU Langone Health.

References

  1. ↑ Onuora, Sarah (1 December 2020). "Somatic mutations cause VEXAS syndrome". Nature Reviews Rheumatology. 17 (1): 1. doi:10.1038/s41584-020-00559-x. ISSN   1759-4790. PMID   33262468. S2CID   227236646.
  2. ↑ Mathews, Stephanie (4 November 2020). "NIH Researchers Discover a New Inflammatory Disease Called VEXAS". National Institute of Arthritis and Musculoskeletal and Skin Diseases. Archived from the original on 10 November 2020. Retrieved 17 November 2020.
  3. ↑ Edwards, Erika (27 October 2020). "'The VEXAS syndrome': Scientists discover a rare and deadly inflammatory disorder in men". NBC News. Retrieved 17 November 2020.
  4. ↑ "New inflammatory disease discovered". NIH Research Matters. National Institutes of Health. 3 November 2020. Archived from the original on 1 December 2020. Retrieved 27 November 2020.
  5. ↑ Nelson, Bryn (14 December 2020). "VEXAS: A Newly Identified & Vexing Myeloid-Driven Inflammation". The Rheumatologist. Archived from the original on 19 December 2020. Retrieved 16 December 2020.
  6. ↑ Ganguly, Prabarna (27 October 2020). "Scientists use clues in the human genome to discover new inflammatory syndrome". Genome.gov. National Human Genome Research Institute. Archived from the original on 5 November 2020. Retrieved 17 November 2020.
  7. 1 2 3 4 Grayson, PC; Patel, BA; Young, NS (2021). "VEXAS syndrome". Blood . 137 (26): 3591–3594. doi:10.1182/blood.2021011455. PMC   8462403 . PMID   33971000.
  8. 1 2 Sterling, D; Duncan, ME; Philippidou, M; Salisbury, JR; Kulasekararaj, AG; Basu, TN (2022). "VEXAS syndrome (vacuoles, E1 enzyme, X-linked, autoinflammatory, somatic) for the dermatologist". Journal of the American Academy of Dermatology . 89 (6): 1209–1214. doi:10.1016/j.jaad.2022.01.042. PMID   35121074. S2CID   246498890.
  9. 1 2 3 Beck, David B.; Ferrada, Marcela A.; Sikora, Keith A.; Ombrello, Amanda K.; Collins, Jason C.; Pei, Wuhong; et al. (27 October 2020). "Somatic Mutations in UBA1 and Severe Adult-Onset Autoinflammatory Disease". New England Journal of Medicine. 383 (27): 2628–2638. doi:10.1056/NEJMoa2026834. PMC   7847551 . PMID   33108101.
  10. ↑ Azvolinsky, Anna (February 2022). "The Vexing VEXAS Syndrome". ASH Clinical News. Retrieved 18 July 2022.
  11. ↑ Levy-Lahad, Ephrat; King, Mary-Claire (27 October 2020). "Hiding in Plain Sight — Somatic Mutation in Human Disease". New England Journal of Medicine. 383 (27): 2680–2682. doi:10.1056/NEJMe2030754. PMID   33108100. S2CID   225083761.
  12. ↑ Hasserjian, Robert P. (7 January 2022). "This Year's Best in Hematology Diagnosis: A New Disease Is Discovered". The Hematologist. 19 (1). doi: 10.1182/hem.V19.1.2022117 . ISSN   1551-8779.
  13. ↑ "A Phase II Study of Allogeneic Hematopoietic Stem Cell Transplant for Subjects With VEXAS (Vacuoles, E1 Enzyme, X-linked, Autoinflammatory, Somatic) Syndrome". clinicaltrials.gov. 14 July 2022. Retrieved 18 July 2022.
  14. ↑ Relapsing Polychondritis Foundation (31 March 2022). "The Relapsing Polychondritis Foundation Invests in the Next Phase of VEXAS Research". polychondritis.org. Retrieved 18 July 2022.
  15. ↑ Bammert, David (22 June 2022). "The Relapsing Polychondritis Foundation Invests in Potentially Groundbreaking Collaborative Research". Relapsing Polychondritis. Relapsing Polychondritis Foundation. Retrieved 19 July 2022.{{cite web}}: CS1 maint: date and year (link)
  16. ↑ Beck, David B.; Werner, Achim; Kastner, Daniel L.; Aksentijevich, Ivona (6 May 2022). "Disorders of ubiquitylation: unchained inflammation". Nature Reviews. Rheumatology. 18 (8): 435–447. doi:10.1038/s41584-022-00778-4. ISSN   1759-4804. PMC   9075716 . PMID   35523963.
  17. ↑ "Research". davidbecklab.org. David B. Beck Laboratory. 1 July 2022. Retrieved 19 July 2022.
This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.